瑞舒伐他汀联用雷米普利对急性心肌梗死患者血清hs-CRP及MMP-9水平的影响

目的探讨瑞舒伐他汀联用雷米普利对急性心肌梗死(acute myocardial infarction,AMI)患者血清hs-CRP及MMP-9水平的影响。方法选取AMI患者65例,随机分为2组:A组(n=32)给予瑞舒伐他汀(20 mg·d-1),B组(n=33)用瑞舒伐他汀(20 mg·d-1)联合雷米普利(5 mg·d-1)治疗,2组疗程均为6个月,观察心血管事件发生情况,并设健康对照组(n=30)。测定治疗前后血清中hs-CRP和MMP-9的水平,超声心动图检查,并进行统计学分析。结果 AMI组中血清hs-CRP和MMP-9的水平明显高于对照组(P<0.01);B组在治疗后血清MMP-9的水平明显降低(P<0.01),左室重构发生率低(P<0.01),再发心血管事件也有下降趋势。结论 AMI后给予瑞舒伐他汀联用雷米普利治疗能减少冠状动脉粥样斑块基质成分的降解,达到稳定动脉粥样硬化斑块的作用,改善患者预后。

Influence of rosuvastatin with ramipril on levels of serum hs-CRP and MMP-9 in the acute myocardial infarction patients

Objective To observe the influence of the different doses of rosuvastatin with ramipril on serum hs-CRP, MMP-9 in the patients with acute myocardial infarction. Methods Sixty five patients with AMI were randomly assigned to rosuvastatin (20 mg·d^-1) group (A group，n=32) and rosuvastatin (20 mg·d^-1) with ramipril (5 mg·d^-1) group (B group，n=33)．Thirty healthy subjects were selected as the control group. Before and after treatment，the serum levels of hs-CRP and MMP-9 and parameters of left ventricular remodeling were compared among treatment groups and control group，and the primary end point events were observed and compared between the two treatment groups．Results Serum levels of hs-CRP and MMP-9 were significant higher in the AMI group than that in the control group（P<0.01）．B group had a significantly decrease in serum level of MMP-9（P<0.01） and left ventricular remodeling（P<0.01），and less tendency of primary end point events. Conclusions Rosuvastatin combined with ramipril in the AMI patients can reduce coronary artery atheromatous plaque matrix degradation, achieve the stabilization of atherosclerotic plaque function, and improve the prognosis.